Mr. Peter Bakema reports

LEADING MEDICAL DEVICE / LIFE SCIENCE / HEALTHCARE VETERAN JOEL KANTER JOINS BOARD OF DIRECTORS OF CVR MEDICAL

CVR Medical Corp. has appointed Joel Kanter to the board of directors. Mr. Kanter has served as president of Windy City Inc., a privately held investment firm, since July, 1986. Mr. Kanter is a veteran health care venture capitalist whose family office has financially backed numerous medical device, life science and health care companies throughout his 35-year career. Mr. Kanter has helped create billions in shareholder value, most notably: I-Flow, which was acquired by Kimberly-Clark for $324-million in 2009, Clarisonic, which was acquired by L'Oreal for $525-million in 2011, Prolor BioSciences, which was acquired by OPKO Health in 2013 for $480-million (U.S.), Encore Medical, which was acquired in 2006 by Blackstone for $860-million, and GranCare, which completed a $1.8-billion merger in 1999 with Living Centers of America, led by Apollo Management and Walnut Financial, where he was chief executive officer, which was acquired in a transaction with Tower Hill Capital, which resulted in an increase of $400-million in shareholder value in 1999.

Mr. Kanter currently serves on the board of directors of two public companies, Magna-Labs Inc. and Medite Cancer Diagnostics Inc., and also serves on the boards of several private concerns, including Fibralign Corp., First Wave Technologies, Orpheus Biosciences Inc., Primal Therapies Inc. and Serpin Pharma.

Mr. Kanter is also a current trustee emeritus and past president of the board of trustees of The Langley School in McLean, Va., a former trustee at the Georgetown Day School in Washington, D.C., and of the Union Institute & University, the country's first on-line university. He is also the current board chair of the Black Student Fund and serves on the Kennedy Center's National Committee on the Performing Arts.

Peter Bakema, chairman and chief executive officer of CVR Medical, commented: "We are thrilled to welcome Joel to our board of directors and to have his rare breadth of experience and knowledge going forward. His track record of investment and acquisition success speaks to a visionary quality that we strive for at CVR. His involvement in moving our Carotid Stenotic Scan (CSS) device to market is another confident step towards providing a solution for a major sector of the health care industry beset with high costs and access barriers."

About CVR Medical Corp.

CVR Medical is a health care company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary CSS device. CVR Medical is currently in pivotal clinical trials in preparation for its planned submission to the U.S. Food and Drug Administration.

We seek Safe Harbor.